Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

H1N1 like vaccine coated nanopatch - Vaxxas

Next Previous
Drug Profile

H1N1 like vaccine coated nanopatch - Vaxxas

Alternative Names: A/California/7/2009-(H1N1)-like-vaccine-coated-nanopatch; A/Michigan/45/2015(H1N1)-like-vaccine coated micro-projection array patch; A/Singapore/GP1908/2015 vaccine coated micro-projection array patch; H1N1 vaccine nanopatch - Vaxxas; HD-MAP Influenza A virus vaccine - Vaxxas; Influenza A virus H1N1 subtype vaccine - Vaxxas; Influenza A virus H1N1 vaccine nanopatch - Vaxxas

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxxas
  • Class Influenza A virus H1N1 vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in Australia (Transdermal, Patch)
  • 09 Apr 2021 H1N1 like vaccine coated nanopatch is still in phase I development for Influenza A virus H1N1 subtype (Prevention) (Vaxxas website, April 2021)
  • 09 Apr 2021 H1N1 like vaccine coated nanopatch - Vaxxas is available for licensing as of 09 Apr 2021. https://www.vaxxas.com/contact-us/ (Vaxxas website, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top